Original Article

You have full text access to this OnlineOpen article

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha†

  1. Mitchell L. Shiffman‡,*,
  2. Jennifer Salvatore,
  3. Sarah Hubbard,
  4. Angie Price,
  5. Richard K. Sterling,
  6. R. Todd Stravitz,
  7. Velimir A. Luketic,
  8. Arun J. Sanyal

Article first published online: 8 JUN 2007

DOI: 10.1002/hep.21712

Issue

Hepatology

Hepatology

Volume 46, Issue 2, pages 371–379, August 2007

Additional Information

How to Cite

Shiffman, M. L., Salvatore, J., Hubbard, S., Price, A., Sterling, R. K., Stravitz, R. T., Luketic, V. A. and Sanyal, A. J. (2007), Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology, 46: 371–379. doi: 10.1002/hep.21712

Author Information

  1. Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA

  1. ‡

    fax: 804-828-4945

*Hepatology Section, Virginia Commonwealth University Medical Center, Box 980341, Richmond, VA 23298

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 27 JUL 2007
  2. Article first published online: 8 JUN 2007
  3. Manuscript Accepted: 5 MAR 2007
  4. Manuscript Received: 3 DEC 2006

Funded by

  • Ortho-Biotech and Schering-Plough

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (314K)

References

  • 1
    Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman ML, Reindollar R, et al. Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–965.
  • 2
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Combination of peginterferon alfa-2a (40 kd) plus ribavirin in patients with chronic hepatitis C virus infection. N Eng J Med 2002; 347: 975–982.
  • 3
    Shiffman ML. Side effects of medical therapy for chronic hepatitis C. Ann Hepatol 2004; 3: 5–10.
  • 4
    McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061–1069.
  • 5
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 645–652.
    Direct Link:
  • 6
    Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015–1023.
  • 7
    Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5: 124–129.
  • 8
    Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103–112.
  • 9
    Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131: 1040–1048.
  • 10
    De Franchesi LD, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. HEPATOLOGY 2000; 31: 997–1004.
    Direct Link:
  • 11
    Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 2491–2499.
  • 12
    Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 1302–1311.
  • 13
    Spiegel BM, Chen K, Chiou CF, Robbins S, Younossi ZM. Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. Clin Gastroenterol Hepatol 2005; 3: 1034–1042.
  • 14
    Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. HEPATOLOGY 2004; 40: 1450–1458.
    Direct Link:
  • 15
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981; 1: 431–435.
    Direct Link:
  • 16
    Epogen in Physicians Desk Reference. 60th ed. 2006: 2374–2384.
  • 17
    Darbypoetin in Physicians Desk Reference. 60th ed. 2006: 576–580.
  • 18
    Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy induced anemia: a systematic review of the literature. Clin Ther 2006; 28: 801–831.
  • 19
    Rossert J; Pure Red Cell Aplasia Global Scientific Advisory Board. Erythropoietin-induced, antibody-mediated pure red cell aplasia. Eur J Clin Invest 2005; 35(Suppl 3): 95–99.
  • 20
    Stravitz RT, Chung H, Sterling RK, Luketic VA, Sanyal AJ, Price AS, et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005; 100: 1415–1419.
    Direct Link:
  • 21
    Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. HEPATOLOGY 2006; 44: 1598–1606.
    Direct Link:
  • 22
    Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265–2271.
  • 23
    Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. HEPATOLOGY 2004; 39: 1702–1708.
    Direct Link:
  • 24
    Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470–477.
  • 25
    Jacobson IM, Brown R, Freilich B, Afdhal NH, Kwo P, Santoro J, et al. Weight-based ribavirin dosing increases sustained viral response in patients with chronic hepatitis C: final results of the WIN-R study, A US community based trial [Abstract]. HEPATOLOGY 2005; 42(Suppl 1): 749A.
  • 26
    Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing peginterferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. HEPATOLOGY 2001; 34: 395–403.
    Direct Link:
  • 27
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485–1492.
  • 28
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.
  • 29
    Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. HEPATOLOGY 2005; 41: 275–279.
    Direct Link:
  • 30
    Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19(Suppl 1): 67–75.
  • 31
    Fontana RJ, Everson GT, Tuteja S, Vargus HE, Shiffman ML. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clin Gastroenterol Hepatol 2004; 2: 2183–2197.
  • 32
    Shiffman ML, Vargus HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl 2003; 9: 1129–1144.
    Direct Link:
  • 33
    Telfer PT, Garson JA, Whitby K, Grant PR, Yardumian A, Hoffbrand AV, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol 1997; 98: 850–855.
    Direct Link:
  • 34
    Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transpl 2003; 18: 1573–1580.
View Full Article (HTML) Get PDF (314K)